Roche enters $1.15 billion licensing deal for Sarepta gene therapy

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

from Reuters: Business News https://ift.tt/374Y9B8